Consideration of differences in drug usage between young-onset and elderly-onset rheumatoid arthritis with target of low disease activity
Elderly-onset rheumatoid arthritis (EORA) is reported to differ from young-onset rheumatoid arthritis (YORA) with regard to patient background and drug treatment. We examined the amount of drug administered to patients who achieved low disease activity (LDA) for rheumatoid arthritis at our hospital....
Gespeichert in:
| Veröffentlicht in: | Modern rheumatology 2021-11, Vol.31 (6), p.1094-1099 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1099 |
|---|---|
| container_issue | 6 |
| container_start_page | 1094 |
| container_title | Modern rheumatology |
| container_volume | 31 |
| creator | Kumagai, Kosuke Okumura, Noriaki Amano, Yasutaka Yayama, Takafumi Mimura, Tomohiro Maeda, Tsutomu Kubo, Mitsuhiko Mori, Kanji Barrett-Jolley, Richard Imai, Shinji |
| description | Elderly-onset rheumatoid arthritis (EORA) is reported to differ from young-onset rheumatoid arthritis (YORA) with regard to patient background and drug treatment. We examined the amount of drug administered to patients who achieved low disease activity (LDA) for rheumatoid arthritis at our hospital.
Demographics, clinical history, and treatments were compared between patients with EORA (n = 70) and YORA (n = 190).
There was a significant difference in the average age (73.8 vs. 57.8 years), disease duration (6.66 vs. 14.7 years), and sex (62.9% males vs. 83.7% females), but no difference in rheumatoid factor positivity (85.3% vs. 80.7%), anti-citrullinated peptide antibody positivity (86.5% vs. 87.7%), simplified disease activity index (4.28 vs. 4.59), or disease activity score 28-CRP (1.99 vs. 2.04) in the EORA and YORA groups, respectively. There were also no significant differences in prednisolone use (37.1% vs. 36.3%), amount of methotrexate administered (MTX) (1.45 vs. 1.41 mg), and MTX use (55.7% vs. 65.3%). However, the MTX dose (2.89 vs. 4.09 mg/week, p = .011) and overall biologics use (32.9% vs. 56.3%, p = .0012) were significantly lower in patients with EORA than in those with YORA.
Patients with EORA may be able to achieve LDA with lower drug dosage than those with YORA. |
| doi_str_mv | 10.1080/14397595.2021.1883251 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_33538619</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2486464880</sourcerecordid><originalsourceid>FETCH-LOGICAL-c476t-cea7dcce646f2ae9c80ade7ce769dd1013e73bbb04ef91edf13c1389ebd1a0133</originalsourceid><addsrcrecordid>eNqNkcuO1DAQRSMEYl58AshLJJTGjvOwd6AIBqSR2DBry7HL3UaJPdgOUT6Bvx6H7p4lmpVL5XPrquoWxVuCdwQz_JHUlHcNb3YVrsiOMEarhrwoLrd-2bWYvzzXGboormL8hTFtOOOviwtKG8pawi-Lv7130WoIMlnvkDdIW2MggFMQkXVIh3mP5ij3gAZIC4BDq5_dvsw6SEg6jWDM-nE9dcIB5kkmbzWSIR2CTTaixaYDSjLsM5A9Rr9knwgyApIq2T82rTfFKyPHCG9O73Vx__XLz_5beffj9nv_-a5UddemUoHstFLQ1q2pJHDFsNTQKeharjXBhEJHh2HANRhOQBtCFaGMw6CJzL_0unh_nPsQ_O8ZYhKTjQrGUTrwcxRVzfLsmjGc0eaIquBjDGDEQ7CTDKsgWGwpiHMKYktBnFLIuncni3mYQD-pzmfPwIcjsMDgTVR2O_cThjFuK9zgps0V3sax59O9Tf-i7HNIKUs_HaXWGR8mufgwapHkOvpggnTKRkH_v8wjJN274g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2486464880</pqid></control><display><type>article</type><title>Consideration of differences in drug usage between young-onset and elderly-onset rheumatoid arthritis with target of low disease activity</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><creator>Kumagai, Kosuke ; Okumura, Noriaki ; Amano, Yasutaka ; Yayama, Takafumi ; Mimura, Tomohiro ; Maeda, Tsutomu ; Kubo, Mitsuhiko ; Mori, Kanji ; Barrett-Jolley, Richard ; Imai, Shinji</creator><creatorcontrib>Kumagai, Kosuke ; Okumura, Noriaki ; Amano, Yasutaka ; Yayama, Takafumi ; Mimura, Tomohiro ; Maeda, Tsutomu ; Kubo, Mitsuhiko ; Mori, Kanji ; Barrett-Jolley, Richard ; Imai, Shinji</creatorcontrib><description>Elderly-onset rheumatoid arthritis (EORA) is reported to differ from young-onset rheumatoid arthritis (YORA) with regard to patient background and drug treatment. We examined the amount of drug administered to patients who achieved low disease activity (LDA) for rheumatoid arthritis at our hospital.
Demographics, clinical history, and treatments were compared between patients with EORA (n = 70) and YORA (n = 190).
There was a significant difference in the average age (73.8 vs. 57.8 years), disease duration (6.66 vs. 14.7 years), and sex (62.9% males vs. 83.7% females), but no difference in rheumatoid factor positivity (85.3% vs. 80.7%), anti-citrullinated peptide antibody positivity (86.5% vs. 87.7%), simplified disease activity index (4.28 vs. 4.59), or disease activity score 28-CRP (1.99 vs. 2.04) in the EORA and YORA groups, respectively. There were also no significant differences in prednisolone use (37.1% vs. 36.3%), amount of methotrexate administered (MTX) (1.45 vs. 1.41 mg), and MTX use (55.7% vs. 65.3%). However, the MTX dose (2.89 vs. 4.09 mg/week, p = .011) and overall biologics use (32.9% vs. 56.3%, p = .0012) were significantly lower in patients with EORA than in those with YORA.
Patients with EORA may be able to achieve LDA with lower drug dosage than those with YORA.</description><identifier>ISSN: 1439-7595</identifier><identifier>EISSN: 1439-7609</identifier><identifier>DOI: 10.1080/14397595.2021.1883251</identifier><identifier>PMID: 33538619</identifier><language>eng</language><publisher>OXFORD: Taylor & Francis</publisher><subject>Age of Onset ; Aged ; Antirheumatic Agents - therapeutic use ; Arthritis, Rheumatoid - diagnosis ; Arthritis, Rheumatoid - drug therapy ; Disease activity score 28-CRP ; elderly-onset rheumatoid arthritis ; Female ; Humans ; Life Sciences & Biomedicine ; low disease activity ; Male ; Methotrexate - therapeutic use ; Middle Aged ; Rheumatoid Factor ; Rheumatology ; Science & Technology ; simplified disease activity index ; young-onset rheumatoid arthritis</subject><ispartof>Modern rheumatology, 2021-11, Vol.31 (6), p.1094-1099</ispartof><rights>2021 Japan College of Rheumatology 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>4</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000620505600001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c476t-cea7dcce646f2ae9c80ade7ce769dd1013e73bbb04ef91edf13c1389ebd1a0133</citedby><cites>FETCH-LOGICAL-c476t-cea7dcce646f2ae9c80ade7ce769dd1013e73bbb04ef91edf13c1389ebd1a0133</cites><orcidid>0000-0002-1975-2339 ; 0000-0003-0449-9972 ; 0000-0002-6934-0877 ; 0000-0002-3206-2391 ; 0000-0003-4392-9795 ; 0000-0001-8802-0601 ; 0000-0003-2766-5937</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930,39263</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33538619$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kumagai, Kosuke</creatorcontrib><creatorcontrib>Okumura, Noriaki</creatorcontrib><creatorcontrib>Amano, Yasutaka</creatorcontrib><creatorcontrib>Yayama, Takafumi</creatorcontrib><creatorcontrib>Mimura, Tomohiro</creatorcontrib><creatorcontrib>Maeda, Tsutomu</creatorcontrib><creatorcontrib>Kubo, Mitsuhiko</creatorcontrib><creatorcontrib>Mori, Kanji</creatorcontrib><creatorcontrib>Barrett-Jolley, Richard</creatorcontrib><creatorcontrib>Imai, Shinji</creatorcontrib><title>Consideration of differences in drug usage between young-onset and elderly-onset rheumatoid arthritis with target of low disease activity</title><title>Modern rheumatology</title><addtitle>MOD RHEUMATOL</addtitle><addtitle>Mod Rheumatol</addtitle><description>Elderly-onset rheumatoid arthritis (EORA) is reported to differ from young-onset rheumatoid arthritis (YORA) with regard to patient background and drug treatment. We examined the amount of drug administered to patients who achieved low disease activity (LDA) for rheumatoid arthritis at our hospital.
Demographics, clinical history, and treatments were compared between patients with EORA (n = 70) and YORA (n = 190).
There was a significant difference in the average age (73.8 vs. 57.8 years), disease duration (6.66 vs. 14.7 years), and sex (62.9% males vs. 83.7% females), but no difference in rheumatoid factor positivity (85.3% vs. 80.7%), anti-citrullinated peptide antibody positivity (86.5% vs. 87.7%), simplified disease activity index (4.28 vs. 4.59), or disease activity score 28-CRP (1.99 vs. 2.04) in the EORA and YORA groups, respectively. There were also no significant differences in prednisolone use (37.1% vs. 36.3%), amount of methotrexate administered (MTX) (1.45 vs. 1.41 mg), and MTX use (55.7% vs. 65.3%). However, the MTX dose (2.89 vs. 4.09 mg/week, p = .011) and overall biologics use (32.9% vs. 56.3%, p = .0012) were significantly lower in patients with EORA than in those with YORA.
Patients with EORA may be able to achieve LDA with lower drug dosage than those with YORA.</description><subject>Age of Onset</subject><subject>Aged</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Arthritis, Rheumatoid - diagnosis</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Disease activity score 28-CRP</subject><subject>elderly-onset rheumatoid arthritis</subject><subject>Female</subject><subject>Humans</subject><subject>Life Sciences & Biomedicine</subject><subject>low disease activity</subject><subject>Male</subject><subject>Methotrexate - therapeutic use</subject><subject>Middle Aged</subject><subject>Rheumatoid Factor</subject><subject>Rheumatology</subject><subject>Science & Technology</subject><subject>simplified disease activity index</subject><subject>young-onset rheumatoid arthritis</subject><issn>1439-7595</issn><issn>1439-7609</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>HGBXW</sourceid><sourceid>EIF</sourceid><recordid>eNqNkcuO1DAQRSMEYl58AshLJJTGjvOwd6AIBqSR2DBry7HL3UaJPdgOUT6Bvx6H7p4lmpVL5XPrquoWxVuCdwQz_JHUlHcNb3YVrsiOMEarhrwoLrd-2bWYvzzXGboormL8hTFtOOOviwtKG8pawi-Lv7130WoIMlnvkDdIW2MggFMQkXVIh3mP5ij3gAZIC4BDq5_dvsw6SEg6jWDM-nE9dcIB5kkmbzWSIR2CTTaixaYDSjLsM5A9Rr9knwgyApIq2T82rTfFKyPHCG9O73Vx__XLz_5beffj9nv_-a5UddemUoHstFLQ1q2pJHDFsNTQKeharjXBhEJHh2HANRhOQBtCFaGMw6CJzL_0unh_nPsQ_O8ZYhKTjQrGUTrwcxRVzfLsmjGc0eaIquBjDGDEQ7CTDKsgWGwpiHMKYktBnFLIuncni3mYQD-pzmfPwIcjsMDgTVR2O_cThjFuK9zgps0V3sax59O9Tf-i7HNIKUs_HaXWGR8mufgwapHkOvpggnTKRkH_v8wjJN274g</recordid><startdate>20211102</startdate><enddate>20211102</enddate><creator>Kumagai, Kosuke</creator><creator>Okumura, Noriaki</creator><creator>Amano, Yasutaka</creator><creator>Yayama, Takafumi</creator><creator>Mimura, Tomohiro</creator><creator>Maeda, Tsutomu</creator><creator>Kubo, Mitsuhiko</creator><creator>Mori, Kanji</creator><creator>Barrett-Jolley, Richard</creator><creator>Imai, Shinji</creator><general>Taylor & Francis</general><general>Oxford Univ Press</general><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1975-2339</orcidid><orcidid>https://orcid.org/0000-0003-0449-9972</orcidid><orcidid>https://orcid.org/0000-0002-6934-0877</orcidid><orcidid>https://orcid.org/0000-0002-3206-2391</orcidid><orcidid>https://orcid.org/0000-0003-4392-9795</orcidid><orcidid>https://orcid.org/0000-0001-8802-0601</orcidid><orcidid>https://orcid.org/0000-0003-2766-5937</orcidid></search><sort><creationdate>20211102</creationdate><title>Consideration of differences in drug usage between young-onset and elderly-onset rheumatoid arthritis with target of low disease activity</title><author>Kumagai, Kosuke ; Okumura, Noriaki ; Amano, Yasutaka ; Yayama, Takafumi ; Mimura, Tomohiro ; Maeda, Tsutomu ; Kubo, Mitsuhiko ; Mori, Kanji ; Barrett-Jolley, Richard ; Imai, Shinji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c476t-cea7dcce646f2ae9c80ade7ce769dd1013e73bbb04ef91edf13c1389ebd1a0133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Age of Onset</topic><topic>Aged</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Arthritis, Rheumatoid - diagnosis</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Disease activity score 28-CRP</topic><topic>elderly-onset rheumatoid arthritis</topic><topic>Female</topic><topic>Humans</topic><topic>Life Sciences & Biomedicine</topic><topic>low disease activity</topic><topic>Male</topic><topic>Methotrexate - therapeutic use</topic><topic>Middle Aged</topic><topic>Rheumatoid Factor</topic><topic>Rheumatology</topic><topic>Science & Technology</topic><topic>simplified disease activity index</topic><topic>young-onset rheumatoid arthritis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kumagai, Kosuke</creatorcontrib><creatorcontrib>Okumura, Noriaki</creatorcontrib><creatorcontrib>Amano, Yasutaka</creatorcontrib><creatorcontrib>Yayama, Takafumi</creatorcontrib><creatorcontrib>Mimura, Tomohiro</creatorcontrib><creatorcontrib>Maeda, Tsutomu</creatorcontrib><creatorcontrib>Kubo, Mitsuhiko</creatorcontrib><creatorcontrib>Mori, Kanji</creatorcontrib><creatorcontrib>Barrett-Jolley, Richard</creatorcontrib><creatorcontrib>Imai, Shinji</creatorcontrib><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Modern rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kumagai, Kosuke</au><au>Okumura, Noriaki</au><au>Amano, Yasutaka</au><au>Yayama, Takafumi</au><au>Mimura, Tomohiro</au><au>Maeda, Tsutomu</au><au>Kubo, Mitsuhiko</au><au>Mori, Kanji</au><au>Barrett-Jolley, Richard</au><au>Imai, Shinji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Consideration of differences in drug usage between young-onset and elderly-onset rheumatoid arthritis with target of low disease activity</atitle><jtitle>Modern rheumatology</jtitle><stitle>MOD RHEUMATOL</stitle><addtitle>Mod Rheumatol</addtitle><date>2021-11-02</date><risdate>2021</risdate><volume>31</volume><issue>6</issue><spage>1094</spage><epage>1099</epage><pages>1094-1099</pages><issn>1439-7595</issn><eissn>1439-7609</eissn><abstract>Elderly-onset rheumatoid arthritis (EORA) is reported to differ from young-onset rheumatoid arthritis (YORA) with regard to patient background and drug treatment. We examined the amount of drug administered to patients who achieved low disease activity (LDA) for rheumatoid arthritis at our hospital.
Demographics, clinical history, and treatments were compared between patients with EORA (n = 70) and YORA (n = 190).
There was a significant difference in the average age (73.8 vs. 57.8 years), disease duration (6.66 vs. 14.7 years), and sex (62.9% males vs. 83.7% females), but no difference in rheumatoid factor positivity (85.3% vs. 80.7%), anti-citrullinated peptide antibody positivity (86.5% vs. 87.7%), simplified disease activity index (4.28 vs. 4.59), or disease activity score 28-CRP (1.99 vs. 2.04) in the EORA and YORA groups, respectively. There were also no significant differences in prednisolone use (37.1% vs. 36.3%), amount of methotrexate administered (MTX) (1.45 vs. 1.41 mg), and MTX use (55.7% vs. 65.3%). However, the MTX dose (2.89 vs. 4.09 mg/week, p = .011) and overall biologics use (32.9% vs. 56.3%, p = .0012) were significantly lower in patients with EORA than in those with YORA.
Patients with EORA may be able to achieve LDA with lower drug dosage than those with YORA.</abstract><cop>OXFORD</cop><pub>Taylor & Francis</pub><pmid>33538619</pmid><doi>10.1080/14397595.2021.1883251</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0002-1975-2339</orcidid><orcidid>https://orcid.org/0000-0003-0449-9972</orcidid><orcidid>https://orcid.org/0000-0002-6934-0877</orcidid><orcidid>https://orcid.org/0000-0002-3206-2391</orcidid><orcidid>https://orcid.org/0000-0003-4392-9795</orcidid><orcidid>https://orcid.org/0000-0001-8802-0601</orcidid><orcidid>https://orcid.org/0000-0003-2766-5937</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1439-7595 |
| ispartof | Modern rheumatology, 2021-11, Vol.31 (6), p.1094-1099 |
| issn | 1439-7595 1439-7609 |
| language | eng |
| recordid | cdi_pubmed_primary_33538619 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /> |
| subjects | Age of Onset Aged Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - diagnosis Arthritis, Rheumatoid - drug therapy Disease activity score 28-CRP elderly-onset rheumatoid arthritis Female Humans Life Sciences & Biomedicine low disease activity Male Methotrexate - therapeutic use Middle Aged Rheumatoid Factor Rheumatology Science & Technology simplified disease activity index young-onset rheumatoid arthritis |
| title | Consideration of differences in drug usage between young-onset and elderly-onset rheumatoid arthritis with target of low disease activity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T09%3A41%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Consideration%20of%20differences%20in%20drug%20usage%20between%20young-onset%20and%20elderly-onset%20rheumatoid%20arthritis%20with%20target%20of%20low%20disease%20activity&rft.jtitle=Modern%20rheumatology&rft.au=Kumagai,%20Kosuke&rft.date=2021-11-02&rft.volume=31&rft.issue=6&rft.spage=1094&rft.epage=1099&rft.pages=1094-1099&rft.issn=1439-7595&rft.eissn=1439-7609&rft_id=info:doi/10.1080/14397595.2021.1883251&rft_dat=%3Cproquest_pubme%3E2486464880%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2486464880&rft_id=info:pmid/33538619&rfr_iscdi=true |